The European Commission announced on Wednesday it has signed a preliminary deal to buy up to 200 million doses of a promising COVID-19 vaccine from U.S. pharmaceutical firm Novavax.

The advance purchase agreement was contingent on the Novavax vaccine being approved by the EU's regulator, the European Medicines Agency, the commission said in a statement.